Lifitegrast — Discount Pricing
Lifitegrast is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Lifitegrast Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $180.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Lifitegrast
Lifitegrast is a prescription medication. Ask your doctor if Lifitegrast is right for you.
How to Check Lifitegrast Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Lifitegrast at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Ophthalmology
About Lifitegrast
Lifitegrast is a prescription eye drop specifically designed to treat the signs and symptoms of chronic dry eye disease. By targeting inflammation, it offers a unique approach to relief. Understanding its role in eye health and potential costs is crucial, and that's where TheDrugClub steps in, helping members access potential savings on this important medication.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Lifitegrast is approved for (FDA label)
Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED). ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: August 18, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Lifitegrast (FDA label)
Ophthalmic solution containing lifitegrast 50 mg/mL (5%). Ophthalmic solution containing lifitegrast 50 mg/mL (5%). ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 8589d376-ac10-4ddb-9c53-2e0c8d5675c4. SPL document ID: 3cabbaea-c2bf-971c-e063-6394a90a4931. Label effective date: August 18, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Lifitegrast (FDA label)
The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4)] The most common adverse reactions (incidence 5%-25%) following the use of Xiidra were instillation-site irritation, dysgeusia, and decreased visual acuity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 8589d376-ac10-4ddb-9c53-2e0c8d5675c4. SPL document ID: 3cabbaea-c2bf-971c-e063-6394a90a4931. Label effective date: August 18, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Lifitegrast (FDA label)
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation [see Adverse Reactions (6.2)] . Hypersensitivity. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 8589d376-ac10-4ddb-9c53-2e0c8d5675c4. SPL document ID: 3cabbaea-c2bf-971c-e063-6394a90a4931. Label effective date: August 18, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.